Tags

Type your tag names separated by a space and hit enter

Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease.
J Am Geriatr Soc. 2000 Jun; 48(6):692-8.JA

Abstract

Catechol-O-methyltransferase (COMT) inhibitors are a new therapeutic option in the treatment of patients with Parkinson's disease. COMT inhibitors act by extending the duration of action of levodopa, thus improving the amount of time a patient can experience benefit from levodopa. COMT inhibitors are only used in conjunction with levodopa. They do have a propensity to augment dopaminergic effects, such that levodopa doses might need to be adjusted downward. Other side effects of COMT inhibitors include diarrhea and liver function abnormalities. Due to the latter, recent guidelines have been developed to monitor patients on tolcapone for this rare side effect, and these guidelines will be discussed. This article also provides representative case histories for the appropriate use of COMT inhibitors that illustrate how these drugs can be used to manage patients with a fluctuating response to levodopa.

Authors+Show Affiliations

Columbia University, Department of Neurology, New York, New York 10032, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

10855610

Citation

Waters, C. "Catechol-O-methyltransferase (COMT) Inhibitors in Parkinson's Disease." Journal of the American Geriatrics Society, vol. 48, no. 6, 2000, pp. 692-8.
Waters C. Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease. J Am Geriatr Soc. 2000;48(6):692-8.
Waters, C. (2000). Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease. Journal of the American Geriatrics Society, 48(6), 692-8.
Waters C. Catechol-O-methyltransferase (COMT) Inhibitors in Parkinson's Disease. J Am Geriatr Soc. 2000;48(6):692-8. PubMed PMID: 10855610.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease. A1 - Waters,C, PY - 2000/6/16/pubmed PY - 2000/7/6/medline PY - 2000/6/16/entrez SP - 692 EP - 8 JF - Journal of the American Geriatrics Society JO - J Am Geriatr Soc VL - 48 IS - 6 N2 - Catechol-O-methyltransferase (COMT) inhibitors are a new therapeutic option in the treatment of patients with Parkinson's disease. COMT inhibitors act by extending the duration of action of levodopa, thus improving the amount of time a patient can experience benefit from levodopa. COMT inhibitors are only used in conjunction with levodopa. They do have a propensity to augment dopaminergic effects, such that levodopa doses might need to be adjusted downward. Other side effects of COMT inhibitors include diarrhea and liver function abnormalities. Due to the latter, recent guidelines have been developed to monitor patients on tolcapone for this rare side effect, and these guidelines will be discussed. This article also provides representative case histories for the appropriate use of COMT inhibitors that illustrate how these drugs can be used to manage patients with a fluctuating response to levodopa. SN - 0002-8614 UR - https://www.unboundmedicine.com/medline/citation/10855610/Catechol_O_methyltransferase__COMT__inhibitors_in_Parkinson's_disease_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0002-8614&date=2000&volume=48&issue=6&spage=692 DB - PRIME DP - Unbound Medicine ER -